- Jin-Ling Tang, professor (jltang@cuhk.edu.hk)1
- 1 Hong Kong Cochrane Branch, Chinese University of Hong Kong, Hong Kong, China
- Correspondence to: J L Tang, The Chinese Cochrane Centre Hong Kong Branch, School of Public Health, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
Introduction
Evidence based medicine re-emphasises applied clinical research in human subjects.12 However, research in traditional Chinese medicine has had a mechanism centred approach and has been dominated by studies of basic and intermediate mechanisms. Though tremendous efforts have been made, and despite occasional successes, such as in acupuncture,3 most questions—for example, the nature of disease in traditional Chinese medicine—have not been satisfactorily answered.4
According to Liang, “Since the early 1990s, the search for the nature of disease has descended into a downward spiral. All the breakthroughs once cheerily anticipated seemed to have become an illusion. The entire traditional Chinese medicine research is currently in a state of disarray. Basic research had come to a standstill. What has gone wrong? Where should we go from here?”4 In this article, I argue that research priorities in traditional Chinese medicine need to be reviewed, and I propose an efficacy driven strategy.
Two possible approaches to research
The mechanism centred approach is primarily concerned with the search for the molecular, cellular, and pharmacological bases of traditional medicines. It seeks to identify the active substances of herbal treatments and investigate the mechanism of action. This strategy is shaped by a belief that traditional Chinese medicine need not be evaluated,5 by the general prosperity of basic biomedical sciences, and by drug development models in conventional medicine. As many research activities in traditional Chinese medicine aim to develop new drugs, the model used by conventional medicine to design and develop new drugs, such as drugs for cancer,6 seems directly relevant.7 It has three important conventions (fig 1, left). Firstly, the potential drug must be a single chemical entity, or a combination of known …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Ethical considerations
Published 14 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 14 February 2012
Re: Raised inflammatory markers
Published 14 February 2012
Re: Physical activity for cancer survivors: meta-analysis of randomised controlled trials
Published 14 February 2012
Smokefree cars in Wales: Laws are better
Published 14 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (8 responses)
Published 1 Feb 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012